Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Finance

Two more biotechs get ready for IPOs

by Laura Howes
August 31, 2023 | A version of this story appeared in Volume 101, Issue 29

 

RayzeBio and Neumora Therapeutics are preparing for initial public offerings (IPOs), according to filings with the US Securities and Exchange Commission. Razye, a radiopharmaceutical firm, will use its IPO proceeds to advance its lead candidate, RYZ101, and develop several other assets. Neumora will advance its pipeline of clinical and preclinical candidates to treat depression. The momentum behind biotech IPOs has stalled since the heady days of 2021, but a recent report from SVB suggests that the market may slowly be coming back.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.